Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Exelixis announced positive topline results from its STELLAR-303 Phase 3 trial, where zanzalintinib combined with Roche's Tecentriq demonstrated a statistically significant improvement in overall survival compared to Bayer's Stivarga for previously treated non-MSI-high metastatic colorectal cancer. This marks the first pivotal success for the zanzalintinib program, with analysts projecting risk-adjusted U.S. peak sales of $875 million for this indication, contributing to Exelixis' broader target of $5 billion in zanzalintinib sales by 2033. The positive outcome, coupled with a consistent safety profile, underscores the drug's commercial potential and led to an 11.1% surge in EXEL stock, reinforcing its perceived defensive investment profile.

Analysis

Exelixis has announced a significant clinical success with positive topline results from its STELLAR-303 Phase 3 trial, demonstrating a statistically significant improvement in overall survival for its drug zanzalintinib combined with Roche's Tecentriq versus Bayer's Stivarga in metastatic colorectal cancer. This outcome marks the first pivotal trial success for the zanzalintinib program, substantially de-risking a key pipeline asset and providing a clear validation of its therapeutic potential. The market has reacted strongly, with EXEL stock surging 11.1%, reflecting investor confidence in the drug's commercial prospects. Analysts at William Blair have quantified this opportunity, projecting risk-adjusted U.S. peak sales of $875 million for this indication alone, which serves as a crucial first step toward management's broader goal of $5 billion in total zanzalintinib sales by 2033. The consistent safety profile with no new signals identified is also a critical factor that will support future regulatory submissions. This positive development, coupled with recent favorable regulatory news for its other drug Cabometyx in Europe, strengthens the analyst view of Exelixis as a company with a 'highly defensive investment profile' underpinned by durable cash flow and a clear path to moderate growth.

Key Decisions for Investors

• Investors should view the positive STELLAR-303 results as a significant de-risking event for Exelixis's pipeline, validating zanzalintinib as a key future growth driver with a clear competitive advantage over Bayer's Stivarga.
• Monitor for upcoming catalysts, including the final analysis of the trial's second primary endpoint in patients without liver metastases and the detailed data presentation at a future medical conference, which could further solidify the drug's value proposition.
• Consider the strengthening of Exelixis's investment profile, which analysts now characterize as highly defensive due to its durable cash flow and a more visible moderate growth trajectory, making it a potentially attractive holding for long-term portfolios.